WebFeb 28, 2024 · SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete... WebApr 12, 2024 · Cytokinetics had a negative return on equity of 1,401.63% and a negative net margin of 410.89%. The firm’s revenue for the quarter was down 96.5% compared to …
Cytokinetics Stops ALS Program After Analysis Finds No Evidence …
WebApr 10, 2024 · For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking Statements. WebJun 24, 2024 · SOUTH SAN FRANCISCO, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has informed the company... daschbosch skin contact
For Cytokinetics, FDA rejection of heart drug would help, not hinder
WebFeb 27, 2024 · On Feb. 28, the FDA is set to decide on Cytokinetics ’ omecamtiv mecarbil (OM), a novel, selective cardiac myosin activator being evaluated for heart failure with reduced ejection fraction. The regulatory agency accepted the New Drug Application for OM in February 2024 and initially set a target action date of Nov. 30, 2024. WebWebsite: www.cytokinetics.com Headquarters: South San Francisco, CA Size: 201 to 500 Employees Founded: 1997 Type: Company - Public (CYTK) Industry: Biotech & Pharmaceuticals Revenue: Unknown / Non-Applicable Competitors: Ionis Pharmaceuticals, MyoKardia, PTC Therapeutics Create Comparison WebSee Tweets about #cytokines2024 on Twitter. See what people are saying and join the conversation. dasche basketball tournament